Clarithromycin
Product Images NDC 63304-821

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clarithromycin (NDC 63304-821). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ranbaxy Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

125 mg 100's Bottle Label (Clarisusp1)

Clarithromycin for Oral Suspension, USP 125 mg/5 mL bottle label by Ranbaxy Pharmaceuticals Inc. The label specifies 100 mL volume when reconstituted. It includes dosage instructions, NDC 63304-821-04, storage conditions, and a barcode. The label also states Rx only and manufacturing information from Ranbaxy Laboratories Limited, India.*

FDA Label Image

250 mg 100's Bottle Label (Clarisusp2)

Label for Clarithromycin oral suspension, USP, 250 mg/5 mL, with a container size of 100 mL when reconstituted. The product is labeled by Ranbaxy Pharmaceuticals Inc. The label includes dosing and preparation instructions, storage conditions, and barcode information. "Rx only" is indicated.*

FDA Label Image

250 mg 60's Bottle Label (Claritab1)

Clarithromycin Tablets, USP 250 mg by Ranbaxy Pharmaceuticals Inc. The label shows a container for 60 tablets, labeled for prescription use only. It includes dosage strength, storage instructions, and safety warnings. The label also features two barcodes and printing indicating lot and expiration date areas.*

FDA Label Image

500 mg 60's Bottle Label (Claritab2)

Clarithromycin 500 mg tablets label from Ranbaxy Pharmaceuticals Inc. The label indicates the product is for prescription use only (Rx only) and contains 60 tablets. It includes dosage and storage information, the National Drug Code (NDC) 63304-726-60, manufacturer details, and a barcode. The label also notes a non-tamish area and batch and expiration date fields.*

FDA Label Image

Clinical Signs Of Mac (Clinicalsigns)

A data table showing clinical response percentages for Clarithromycin doses (500 mg, 1000 mg, 2000 mg b.i.d.) in four categories: resolution of fever, resolution of night sweats, weight gain over 3%, and hemoglobin increase over 1 gram, with columns indicating percent ever and percent at or after six weeks treatment.*

FDA Label Image

Eradication Rates (Eradicatrates)

A data table showing H. pylori eradication rates in Study H2BA-3001 comparing RBC 400 mg plus Clarithromycin 500 mg b.i.d. versus t.i.d. The table presents ITT and Per-Protocol analysis results, including percentages, confidence intervals, and 95% confidence interval rate differences.*

FDA Label Image

Survival (Figure1)

A survival curve chart comparing the proportion of survivors over time measured in days since randomization for Clarithromycin versus placebo. The chart shows two lines indicating survival proportions, one for Clarithromycin and one for placebo, with survival decreasing gradually over approximately 700 days.*

FDA Label Image

Mic Ranges (Qcranges)

A data table listing antimicrobial agents and their minimum inhibitory concentration (MIC) ranges against H. pylori ATCC 43504. The agents included are Clarithromycin and Amoxicillin, each with MIC ranges from 0.015 to 0.12 mcg/mL.*

FDA Label Image

Structural Formula (Structure)

Chemical structure of clarithromycin, showing its complex macrolide ring with multiple methyl, hydroxyl, and methoxy groups, as well as attached sugar moieties. The structure includes detailed atoms and bonds arranged in a typical clarithromycin molecular configuration.*

FDA Label Image

Test Results (Testresults)

A data table titled "Clarithromycin Susceptibility Test Results and Clinical/Bacteriological Outcomes" listing pretreatment and post-treatment results against H. pylori bacteria. The table presents susceptibility, intermediate, and resistant counts for various treatment regimens including combinations of clarithromycin with omeprazole, ranitidine bismuth citrate, and amoxicillin, each with differing dosages and durations. Results are categorized by bacterial eradication status and minimum inhibitory concentrations (MIC). The labeler, Ranbaxy Pharmaceuticals Inc., is associated with the clarithromycin product.*

FDA Label Image

Susceptibility Tests (Testwithhpylori)

A data table displaying susceptibility test interpretive criteria for H. pylori, including clarithromycin MIC values (mcg/mL) categorized as susceptible, intermediate, or resistant, and amoxicillin MIC values with interpretation for susceptibility.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.